Diabetes, DPP-4 Inhibitors

• Newer Diabetes Drugs - Aug 06, 2020
• Newer Diabetes Treatments - Jul 26, 2018
• Diabetes Class Update - Sep 28, 2017

• Newer Diabetes Medications and Combinations - Sep 29, 2016
• Diabetes mellitus - Sep 24, 2015
• Diabetes Mellitus - Sep 23, 2014
• Class Update: Newer drugs for Diabetes - Sep 26, 2013

• September 2020 - Cardiovascular Outcomes Associated with Newer Therapy Classes for Type 2 Diabetes Mellitus
• September 2018 - Management Strategies for Patients with Prediabetes
• March 2016 - Antidiabetic Treatments and Cardiovascular Implications

• February 2016 - 2015 in Review: Relevant Safety Updates and Ongoing Safety Concerns
• October 2013 - Updates and Comparisons of Type 2 Diabetes Treatment Guidelines
• June 2012 - Can The Diabetic War Be Fought By Aggressive Blood Pressure Control?

Y = preferred
N = non-preferred. Non-preferred drugs listed as N but without clinical drug use criteria are subject to the Non-Preferred Drugs in Select PDL Classes prior authorization criteria. New drugs will be listed as N until reviewed by the P&T Committee and are subject to the New Drug Policy.
V = voluntary non-preferred. Non-preferred mental health drugs are listed as V and prior authorization is not required.
Null (i.e. blank) = indicates the class or specific drug has not been reviewed for PDL placement.